5-fluoro-2,2'-cyclocytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-fluoro-2,2'-cyclocytidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	124482
MeSH ID	M0057265

Synonyms (8)

Synonym
40505-45-1
flurocitabine hydrochloride
2,2'-anhydro-1-beta-d-arabinofuranosyl-5-fluorocytosine
5-fluoro-2,2'-cyclocytidine
anhydro-ara-5-fluorocytosine
386064mqor ,
unii-386064mqor
(2r,4r,5r)-11-fluoro-4-(hydroxymethyl)-10-imino-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-5-ol;hydrochloride

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.50 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
busulfan [no description available]	1.96	1	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
dimethylmyleran dimethylmyleran: RN given refers to cpd without isomeric designation. dimethylmyleran : A methanesulfonate ester that is hexane-2,5-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups.	1.96	1	0	methanesulfonate ester	alkylating agent; mutagen
cytarabine [no description available]	4.26	4	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
ancitabine Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.	4.44	5	1	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	1.95	1	0	N-alkylpiperazine
diaziquone diaziquone: RN given refers to parent cpd. diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.	1.97	1	0	1,4-benzoquinones; aziridines; carbamate ester; enamine	alkylating agent; antineoplastic agent
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.34	1	1	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent

Condition	Relationship Strength	Studies	Trials
Cancer of Gastrointestinal Tract [description not available]	1.95	1	0
Leukocytopenia [description not available]	1.95	1	0
Emesis [description not available]	1.95	1	0
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	1.95	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	1.95	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	1.95	1	0
Leucocythaemia [description not available]	3.34	1	1
Acute Myelogenous Leukemia [description not available]	3.75	2	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	3.34	1	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	3.75	2	1
Experimental Leukemia [description not available]	1.96	1	0
Experimental Neoplasms [description not available]	1.96	1	0
EHS Tumor [description not available]	1.96	1	0
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	1.95	1	0
Adenocarcinoma, Basal Cell [description not available]	1.95	1	0
Cancer of Digestive System [description not available]	1.95	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.95	1	0
Digestive System Neoplasms Tumors or cancer of the DIGESTIVE SYSTEM.	1.95	1	0

chemdatabank.com